XML 30 R11.htm IDEA: XBRL DOCUMENT v3.22.1
Fair Value Measurements
12 Months Ended
Dec. 31, 2021
Fair Value Disclosures [Abstract]  
Fair Value Measurements

Note 4 – Fair Value Measurements

 

The Company measures and records certain financial assets and liabilities at fair value on a recurring basis. Fair value is based on the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

 

The following three levels of inputs are used to measure the fair value of financial assets and liabilities:

 

Level 1: Quoted market prices in active markets for identical assets or liabilities.

 

Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.

 

Level 3: Unobservable inputs that are not corroborated by market data.

 

 

The following table summarizes the assets and liabilities measured at fair value on a recurring basis as of December 31, 2021 and December 31, 2020, by level within the fair value hierarchy:

 

   December 31, 2021 
   (Level 1)   (Level 2)   (Level 3)   Total 
Assets:                    
Marketable securities (certificates of deposit)  $-   $1,255,266   $-   $1,255,266 
Total assets measured at fair value  $-   $1,255,266   $-   $1,255,266 
Liabilities:                    
Contingent consideration - common stock  $           -   $      -   $8,684,669   $8,684,669 
Contingent consideration - warrants   -    -    1,747,972    1,747,972 
Total liabilities measured at fair value  $-   $-   $10,432,641   $10,432,641 

 

   December 31, 2020 
   (Level 1)   (Level 2)   (Level 3)   Total 
Assets:                
Marketable securities (certificates of deposit)  $-   $4,335,446   $             -   $4,335,446 
Total assets measured at fair value  $-   $4,335,446   $-   $4,335,446 

 

The Company’s financial instruments that are measured at fair value on a recurring basis consist of certificates of deposit.

 

In connection with the acquisitions of Idaho Molecular, Inc and Advanced Conceptions, Inc. on December 31, 2021, the Company recorded a liability for contingent consideration in the form of shares of common stock and warrants to purchase common stock. The fair value of contingent consideration is calculated using a discounted probability weighted valuation model. Discount rates used in such calculation are a significant assumption that are not observed in the market, and therefore, the resulting fair value represents a Level 3 measurement.

 

The changes for Level 3 items measured at fair value on a recurring basis are as follows:

 

Fair value as of December 31, 2020  $- 
Contingent considered issued for business acquisitions   10,432,641 
Fair value as of December 31, 2021  $10,432,641 

 

The fair value of the contingent consideration is based on the fair value of the contingent consideration-common stock and contingent consideration-warrants. The fair value of the contingent consideration-common stock is equal to the probability-adjusted value of the Company’s common stock as of December 31, 2021. The fair value of the contingent consideration-warrants is equal to the probability adjusted value of a call option with terms consistent with the terms of the warrants as of December 31, 2021. Prior to the probability adjustments, the warrants were valued based on the following inputs:

 

   December 31, 2021 
Stock price  $8.93 
Strike price  $9.13 
Volatility   80.00%
Risk-free rate   1.30%
Expected term   5.0 

 

 

In order to calculate the probability-adjusted value of the contingent consideration-common stock and contingent consideration-warrants, the Company estimated the probability of achieving certain milestones, which include regulatory approval for identified products, as well as production and net revenue targets. The probability of achieving the milestone related to net revenues was estimated using a Monte Carlo simulation valuation model. The unobservable significant inputs to the valuation model were as follows:

 

   December 31, 2021 
Stock price  $8.93 
Risk-free rate   1.30%
Expected term   5.0 
Weighted-average cost of capital   27.00%
Revenue discount rate   9.50%
Equity volatility   80.00%
Asset volatility   80.00%
Revenue volatility   30.00%

 

Fair Value of Other Financial Instruments

 

The carrying amounts of certain financial instruments, including cash held in banks, accounts receivable, notes receivable, accounts payable, accrued liabilities, and other liabilities approximate fair value due to their short-term maturities and are excluded from the fair value tables above.